August 28, 2024
End-payor plaintiffs asked a New Jersey federal judge Tuesday to give final approval of a $35 million settlement resolving their antitrust claims against Pfizer over the cholesterol medication Lipitor.
The proposed settlement will put an end to claims from the end payors, which represent a class of third-party payors and a class of consumers who purchased, paid, and/or reimbursed for branded Lipitor or generic Lipitor in 24 states and the District of Columbia, that Pfizer conspired with Ranbaxy Laboratories Ltd. to delay the release of a generic Lipitor to monopolize the market.
U.S. District Judge Peter G. Sheridan gave preliminary approval to the settlement on June 3.
. . .
The end payors are represented by Lisa J. Rodriguez of Dilworth Paxson LLP, Sharon Robertson of Cohen Milstein Sellers & Toll PLLC, Kenneth A. Wexler of Wexler Boley & Elgersma LLP, Michael Buchman of Motley Rice LLC and Robert G. Eisler of Grant & Eisenhofer PA.
Read Lipitor Buyers Seek Final OK For $35M Deal In Antitrust Fight.